Angiotensin Converting Enzyme 2 Expression in Human Type II Pneumocytes is Influenced by Renin-Angiotensin System Blockade Article Swipe
Mauro G. Silva
,
Nora Falcoff
,
Gerardo C Corradi
,
José Alfie
,
Rolando F. Seguel
,
Gabriela Tabaj
,
Laura Iglesias
,
Myriam Núñez
,
Gabriela R. Guman
,
Mariela M. Gironacci
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-159733/v1
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-159733/v1
Angiotensin converting enzyme 2 (ACE2) acts as the receptor for the type 2 coronavirus that causes severe acute respiratory syndrome (SARS-CoV2), the etiological agent of coronavirus-19 disease (COVID-19). There has been a growing concern that renin-angiotensin (RAS) blockade increases the expression of ACE2 and then elevate patient susceptibility to SARS-CoV-2. Here, we report that age, smoking and RAS blockade influence on the percentage of human ACE2-expressing type II pneumocytes. These findings may explain the increased susceptibility to COVID-19 with age and in subjects with treated cardiovascular-related pathologies. Enhanced ACE2-expressing type II pneumonocytes would facilitate SARS-CoV2 infection, thus increasing patient susceptibility to acute respiratory distress syndrome development because of an unbalance between the pressor and depressor axis of the RAS due to ACE2 sequestration by the virus.
Related Topics
Concepts
Renin–angiotensin system
Blockade
Angiotensin-converting enzyme 2
Angiotensin-converting enzyme
Enzyme
Angiotensin II
Peptidyl-Dipeptidase A
Chemistry
Endocrinology
Internal medicine
Biology
Biochemistry
Medicine
Receptor
Coronavirus disease 2019 (COVID-19)
Blood pressure
Infectious disease (medical specialty)
Disease
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.21203/rs.3.rs-159733/v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3128829445
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3128829445Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-159733/v1Digital Object Identifier
- Title
-
Angiotensin Converting Enzyme 2 Expression in Human Type II Pneumocytes is Influenced by Renin-Angiotensin System BlockadeWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-02-02Full publication date if available
- Authors
-
Mauro G. Silva, Nora Falcoff, Gerardo C Corradi, José Alfie, Rolando F. Seguel, Gabriela Tabaj, Laura Iglesias, Myriam Núñez, Gabriela R. Guman, Mariela M. GironacciList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-159733/v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.21203/rs.3.rs-159733/v1Direct OA link when available
- Concepts
-
Renin–angiotensin system, Blockade, Angiotensin-converting enzyme 2, Angiotensin-converting enzyme, Enzyme, Angiotensin II, Peptidyl-Dipeptidase A, Chemistry, Endocrinology, Internal medicine, Biology, Biochemistry, Medicine, Receptor, Coronavirus disease 2019 (COVID-19), Blood pressure, Infectious disease (medical specialty), DiseaseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3128829445 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| ids.mag | 3128829445 |
| ids.openalex | https://openalex.org/W3128829445 |
| fwci | 0.0 |
| type | preprint |
| title | Angiotensin Converting Enzyme 2 Expression in Human Type II Pneumocytes is Influenced by Renin-Angiotensin System Blockade |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10375 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.897599995136261 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3004 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Pharmacogenetics and Drug Metabolism |
| topics[1].id | https://openalex.org/T10754 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.8884999752044678 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2713 |
| topics[1].subfield.display_name | Epidemiology |
| topics[1].display_name | Neuroendocrine Tumor Research Advances |
| topics[2].id | https://openalex.org/T11178 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.8496999740600586 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Receptor Mechanisms and Signaling |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C198710026 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8170856237411499 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q898218 |
| concepts[0].display_name | Renin–angiotensin system |
| concepts[1].id | https://openalex.org/C2778468042 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7019880414009094 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q273976 |
| concepts[1].display_name | Blockade |
| concepts[2].id | https://openalex.org/C2775946041 |
| concepts[2].level | 5 |
| concepts[2].score | 0.5659487247467041 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q14875321 |
| concepts[2].display_name | Angiotensin-converting enzyme 2 |
| concepts[3].id | https://openalex.org/C27016395 |
| concepts[3].level | 3 |
| concepts[3].score | 0.48281654715538025 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q128861 |
| concepts[3].display_name | Angiotensin-converting enzyme |
| concepts[4].id | https://openalex.org/C181199279 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4513291120529175 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q8047 |
| concepts[4].display_name | Enzyme |
| concepts[5].id | https://openalex.org/C2908929049 |
| concepts[5].level | 3 |
| concepts[5].score | 0.44834795594215393 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q65963433 |
| concepts[5].display_name | Angiotensin II |
| concepts[6].id | https://openalex.org/C2910482119 |
| concepts[6].level | 4 |
| concepts[6].score | 0.43129950761795044 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128861 |
| concepts[6].display_name | Peptidyl-Dipeptidase A |
| concepts[7].id | https://openalex.org/C185592680 |
| concepts[7].level | 0 |
| concepts[7].score | 0.3668156564235687 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[7].display_name | Chemistry |
| concepts[8].id | https://openalex.org/C134018914 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3530985713005066 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[8].display_name | Endocrinology |
| concepts[9].id | https://openalex.org/C126322002 |
| concepts[9].level | 1 |
| concepts[9].score | 0.34930622577667236 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[9].display_name | Internal medicine |
| concepts[10].id | https://openalex.org/C86803240 |
| concepts[10].level | 0 |
| concepts[10].score | 0.2792227268218994 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[10].display_name | Biology |
| concepts[11].id | https://openalex.org/C55493867 |
| concepts[11].level | 1 |
| concepts[11].score | 0.1805337369441986 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[11].display_name | Biochemistry |
| concepts[12].id | https://openalex.org/C71924100 |
| concepts[12].level | 0 |
| concepts[12].score | 0.17565155029296875 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[12].display_name | Medicine |
| concepts[13].id | https://openalex.org/C170493617 |
| concepts[13].level | 2 |
| concepts[13].score | 0.16332942247390747 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q208467 |
| concepts[13].display_name | Receptor |
| concepts[14].id | https://openalex.org/C3008058167 |
| concepts[14].level | 4 |
| concepts[14].score | 0.06906956434249878 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[14].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[15].id | https://openalex.org/C84393581 |
| concepts[15].level | 2 |
| concepts[15].score | 0.04275012016296387 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q82642 |
| concepts[15].display_name | Blood pressure |
| concepts[16].id | https://openalex.org/C524204448 |
| concepts[16].level | 3 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[16].display_name | Infectious disease (medical specialty) |
| concepts[17].id | https://openalex.org/C2779134260 |
| concepts[17].level | 2 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[17].display_name | Disease |
| keywords[0].id | https://openalex.org/keywords/renin–angiotensin-system |
| keywords[0].score | 0.8170856237411499 |
| keywords[0].display_name | Renin–angiotensin system |
| keywords[1].id | https://openalex.org/keywords/blockade |
| keywords[1].score | 0.7019880414009094 |
| keywords[1].display_name | Blockade |
| keywords[2].id | https://openalex.org/keywords/angiotensin-converting-enzyme-2 |
| keywords[2].score | 0.5659487247467041 |
| keywords[2].display_name | Angiotensin-converting enzyme 2 |
| keywords[3].id | https://openalex.org/keywords/angiotensin-converting-enzyme |
| keywords[3].score | 0.48281654715538025 |
| keywords[3].display_name | Angiotensin-converting enzyme |
| keywords[4].id | https://openalex.org/keywords/enzyme |
| keywords[4].score | 0.4513291120529175 |
| keywords[4].display_name | Enzyme |
| keywords[5].id | https://openalex.org/keywords/angiotensin-ii |
| keywords[5].score | 0.44834795594215393 |
| keywords[5].display_name | Angiotensin II |
| keywords[6].id | https://openalex.org/keywords/peptidyl-dipeptidase-a |
| keywords[6].score | 0.43129950761795044 |
| keywords[6].display_name | Peptidyl-Dipeptidase A |
| keywords[7].id | https://openalex.org/keywords/chemistry |
| keywords[7].score | 0.3668156564235687 |
| keywords[7].display_name | Chemistry |
| keywords[8].id | https://openalex.org/keywords/endocrinology |
| keywords[8].score | 0.3530985713005066 |
| keywords[8].display_name | Endocrinology |
| keywords[9].id | https://openalex.org/keywords/internal-medicine |
| keywords[9].score | 0.34930622577667236 |
| keywords[9].display_name | Internal medicine |
| keywords[10].id | https://openalex.org/keywords/biology |
| keywords[10].score | 0.2792227268218994 |
| keywords[10].display_name | Biology |
| keywords[11].id | https://openalex.org/keywords/biochemistry |
| keywords[11].score | 0.1805337369441986 |
| keywords[11].display_name | Biochemistry |
| keywords[12].id | https://openalex.org/keywords/medicine |
| keywords[12].score | 0.17565155029296875 |
| keywords[12].display_name | Medicine |
| keywords[13].id | https://openalex.org/keywords/receptor |
| keywords[13].score | 0.16332942247390747 |
| keywords[13].display_name | Receptor |
| keywords[14].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[14].score | 0.06906956434249878 |
| keywords[14].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[15].id | https://openalex.org/keywords/blood-pressure |
| keywords[15].score | 0.04275012016296387 |
| keywords[15].display_name | Blood pressure |
| language | en |
| locations[0].id | doi:10.21203/rs.3.rs-159733/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5026300355 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Mauro G. Silva |
| authorships[0].countries | AR |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[0].affiliations[0].raw_affiliation_string | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[0].institutions[0].id | https://openalex.org/I24354313 |
| authorships[0].institutions[0].ror | https://ror.org/0081fs513 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I24354313 |
| authorships[0].institutions[0].country_code | AR |
| authorships[0].institutions[0].display_name | Universidad de Buenos Aires |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mauro G Silva |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[1].author.id | https://openalex.org/A5065312665 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Nora Falcoff |
| authorships[1].countries | CL |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210099415 |
| authorships[1].affiliations[0].raw_affiliation_string | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[1].institutions[0].id | https://openalex.org/I4210099415 |
| authorships[1].institutions[0].ror | https://ror.org/00t0z3q71 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I4210099415, https://openalex.org/I4210109244, https://openalex.org/I4210122724 |
| authorships[1].institutions[0].country_code | CL |
| authorships[1].institutions[0].display_name | Instituto Nacional del Tórax |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Nora L Falcoff |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[2].author.id | https://openalex.org/A5112786770 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Gerardo C Corradi |
| authorships[2].countries | AR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[2].affiliations[0].raw_affiliation_string | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[2].institutions[0].id | https://openalex.org/I24354313 |
| authorships[2].institutions[0].ror | https://ror.org/0081fs513 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I24354313 |
| authorships[2].institutions[0].country_code | AR |
| authorships[2].institutions[0].display_name | Universidad de Buenos Aires |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Gerardo C Corradi |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[3].author.id | https://openalex.org/A5054433985 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-9993-1638 |
| authorships[3].author.display_name | José Alfie |
| authorships[3].affiliations[0].raw_affiliation_string | Hospital Italiano |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | José Alfie |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Hospital Italiano |
| authorships[4].author.id | https://openalex.org/A5042747316 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Rolando F. Seguel |
| authorships[4].countries | CL |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210099415 |
| authorships[4].affiliations[0].raw_affiliation_string | Hospital Prov de Tórax “Dr. A. Cetrángolo” |
| authorships[4].institutions[0].id | https://openalex.org/I4210099415 |
| authorships[4].institutions[0].ror | https://ror.org/00t0z3q71 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210099415, https://openalex.org/I4210109244, https://openalex.org/I4210122724 |
| authorships[4].institutions[0].country_code | CL |
| authorships[4].institutions[0].display_name | Instituto Nacional del Tórax |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Rolando F. Seguel |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Hospital Prov de Tórax “Dr. A. Cetrángolo” |
| authorships[5].author.id | https://openalex.org/A5088238720 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Gabriela Tabaj |
| authorships[5].countries | CL |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210099415 |
| authorships[5].affiliations[0].raw_affiliation_string | Hospital Prov de Tórax “Dr. A. Cetrángolo” |
| authorships[5].institutions[0].id | https://openalex.org/I4210099415 |
| authorships[5].institutions[0].ror | https://ror.org/00t0z3q71 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210099415, https://openalex.org/I4210109244, https://openalex.org/I4210122724 |
| authorships[5].institutions[0].country_code | CL |
| authorships[5].institutions[0].display_name | Instituto Nacional del Tórax |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Gabriela Tabaj |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Hospital Prov de Tórax “Dr. A. Cetrángolo” |
| authorships[6].author.id | https://openalex.org/A5012769630 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Laura Iglesias |
| authorships[6].countries | CL |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210099415 |
| authorships[6].affiliations[0].raw_affiliation_string | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[6].institutions[0].id | https://openalex.org/I4210099415 |
| authorships[6].institutions[0].ror | https://ror.org/00t0z3q71 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210099415, https://openalex.org/I4210109244, https://openalex.org/I4210122724 |
| authorships[6].institutions[0].country_code | CL |
| authorships[6].institutions[0].display_name | Instituto Nacional del Tórax |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Laura Iglesias |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[7].author.id | https://openalex.org/A5104026570 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Myriam Núñez |
| authorships[7].countries | AR |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[7].affiliations[0].raw_affiliation_string | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[7].institutions[0].id | https://openalex.org/I24354313 |
| authorships[7].institutions[0].ror | https://ror.org/0081fs513 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I24354313 |
| authorships[7].institutions[0].country_code | AR |
| authorships[7].institutions[0].display_name | Universidad de Buenos Aires |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Myriam Nuñez |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[8].author.id | https://openalex.org/A5041469942 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Gabriela R. Guman |
| authorships[8].countries | CL |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210099415 |
| authorships[8].affiliations[0].raw_affiliation_string | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[8].institutions[0].id | https://openalex.org/I4210099415 |
| authorships[8].institutions[0].ror | https://ror.org/00t0z3q71 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210099415, https://openalex.org/I4210109244, https://openalex.org/I4210122724 |
| authorships[8].institutions[0].country_code | CL |
| authorships[8].institutions[0].display_name | Instituto Nacional del Tórax |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Gabriela R. Guman |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Hospital Prov de Tórax “Dr. A. Cetrángolo” y Municipal de Vte López “Prof. B. Houssay” |
| authorships[9].author.id | https://openalex.org/A5091131338 |
| authorships[9].author.orcid | https://orcid.org/0000-0002-8189-0388 |
| authorships[9].author.display_name | Mariela M. Gironacci |
| authorships[9].countries | AR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I24354313 |
| authorships[9].affiliations[0].raw_affiliation_string | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| authorships[9].institutions[0].id | https://openalex.org/I24354313 |
| authorships[9].institutions[0].ror | https://ror.org/0081fs513 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I24354313 |
| authorships[9].institutions[0].country_code | AR |
| authorships[9].institutions[0].display_name | Universidad de Buenos Aires |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Mariela M. Gironacci |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Angiotensin Converting Enzyme 2 Expression in Human Type II Pneumocytes is Influenced by Renin-Angiotensin System Blockade |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10375 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.897599995136261 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3004 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Pharmacogenetics and Drug Metabolism |
| related_works | https://openalex.org/W3038023608, https://openalex.org/W4211013118, https://openalex.org/W3158929090, https://openalex.org/W4211233539, https://openalex.org/W3087357679, https://openalex.org/W2015111258, https://openalex.org/W4211164148, https://openalex.org/W3092829494, https://openalex.org/W4396981132, https://openalex.org/W2082133861 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-159733/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-159733/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-159733/v1 |
| publication_date | 2021-02-02 |
| publication_year | 2021 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 4, 13 |
| abstract_inverted_index.a | 32 |
| abstract_inverted_index.II | 68, 91 |
| abstract_inverted_index.an | 109 |
| abstract_inverted_index.as | 7 |
| abstract_inverted_index.by | 124 |
| abstract_inverted_index.in | 82 |
| abstract_inverted_index.of | 25, 42, 64, 108, 117 |
| abstract_inverted_index.on | 61 |
| abstract_inverted_index.to | 49, 77, 101, 121 |
| abstract_inverted_index.we | 52 |
| abstract_inverted_index.RAS | 58, 119 |
| abstract_inverted_index.age | 80 |
| abstract_inverted_index.and | 44, 57, 81, 114 |
| abstract_inverted_index.due | 120 |
| abstract_inverted_index.for | 10 |
| abstract_inverted_index.has | 30 |
| abstract_inverted_index.may | 72 |
| abstract_inverted_index.the | 8, 11, 22, 40, 62, 74, 112, 118, 125 |
| abstract_inverted_index.ACE2 | 43, 122 |
| abstract_inverted_index.acts | 6 |
| abstract_inverted_index.age, | 55 |
| abstract_inverted_index.axis | 116 |
| abstract_inverted_index.been | 31 |
| abstract_inverted_index.that | 15, 35, 54 |
| abstract_inverted_index.then | 45 |
| abstract_inverted_index.thus | 97 |
| abstract_inverted_index.type | 12, 67, 90 |
| abstract_inverted_index.with | 79, 84 |
| abstract_inverted_index.(RAS) | 37 |
| abstract_inverted_index.Here, | 51 |
| abstract_inverted_index.There | 29 |
| abstract_inverted_index.These | 70 |
| abstract_inverted_index.acute | 18, 102 |
| abstract_inverted_index.agent | 24 |
| abstract_inverted_index.human | 65 |
| abstract_inverted_index.would | 93 |
| abstract_inverted_index.(ACE2) | 5 |
| abstract_inverted_index.causes | 16 |
| abstract_inverted_index.enzyme | 3 |
| abstract_inverted_index.report | 53 |
| abstract_inverted_index.severe | 17 |
| abstract_inverted_index.virus. | 126 |
| abstract_inverted_index.because | 107 |
| abstract_inverted_index.between | 111 |
| abstract_inverted_index.concern | 34 |
| abstract_inverted_index.disease | 27 |
| abstract_inverted_index.elevate | 46 |
| abstract_inverted_index.explain | 73 |
| abstract_inverted_index.growing | 33 |
| abstract_inverted_index.patient | 47, 99 |
| abstract_inverted_index.pressor | 113 |
| abstract_inverted_index.smoking | 56 |
| abstract_inverted_index.treated | 85 |
| abstract_inverted_index.COVID-19 | 78 |
| abstract_inverted_index.Enhanced | 88 |
| abstract_inverted_index.blockade | 38, 59 |
| abstract_inverted_index.distress | 104 |
| abstract_inverted_index.findings | 71 |
| abstract_inverted_index.receptor | 9 |
| abstract_inverted_index.subjects | 83 |
| abstract_inverted_index.syndrome | 20, 105 |
| abstract_inverted_index.SARS-CoV2 | 95 |
| abstract_inverted_index.depressor | 115 |
| abstract_inverted_index.increased | 75 |
| abstract_inverted_index.increases | 39 |
| abstract_inverted_index.influence | 60 |
| abstract_inverted_index.unbalance | 110 |
| abstract_inverted_index.converting | 2 |
| abstract_inverted_index.expression | 41 |
| abstract_inverted_index.facilitate | 94 |
| abstract_inverted_index.increasing | 98 |
| abstract_inverted_index.infection, | 96 |
| abstract_inverted_index.percentage | 63 |
| abstract_inverted_index.(COVID-19). | 28 |
| abstract_inverted_index.Angiotensin | 1 |
| abstract_inverted_index.SARS-CoV-2. | 50 |
| abstract_inverted_index.coronavirus | 14 |
| abstract_inverted_index.development | 106 |
| abstract_inverted_index.etiological | 23 |
| abstract_inverted_index.respiratory | 19, 103 |
| abstract_inverted_index.(SARS-CoV2), | 21 |
| abstract_inverted_index.pathologies. | 87 |
| abstract_inverted_index.pneumocytes. | 69 |
| abstract_inverted_index.pneumonocytes | 92 |
| abstract_inverted_index.sequestration | 123 |
| abstract_inverted_index.coronavirus-19 | 26 |
| abstract_inverted_index.susceptibility | 48, 76, 100 |
| abstract_inverted_index.ACE2-expressing | 66, 89 |
| abstract_inverted_index.renin-angiotensin | 36 |
| abstract_inverted_index.cardiovascular-related | 86 |
| abstract_inverted_index.<title>Abstract</title> | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 2 |
| institutions_distinct_count | 10 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8899999856948853 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.0148866 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |